Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model

Vaccine

Volumn 35, Issue 31, 2017, Pages 3850-3858

  Ma, Ying ^a,b   Yang, Andrew ^b   Peng, Shiwen ^b   Qiu, Jin ^b,c   Farmer, Emily ^b   Hung, Chien Fu ^b   Wu, T C ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

DNA vaccine; E6 oncoprotein; HPV18 E6 tumor model; Human papillomavirus 18; Immunotherapy

Indexed keywords

CD8 ANTIGEN; COMPLEMENTARY DNA; DNA VACCINE; EPITOPE; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN E6; DNA BINDING PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; ONCOPROTEIN; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA IMMUNIZATION; ELECTROPORATION; FEMALE; FLOW CYTOMETRY; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; TUMOR IMMUNITY; TUMOR MODEL; VACCINE IMMUNOGENICITY; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL PROLIFERATION; COMPLICATION; DISEASE MODEL; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; PAPILLOMAVIRUS INFECTION; PATHOLOGY; SQUAMOUS CELL CARCINOMA; VIROLOGY;

ADENOCARCINOMA; ANIMALS; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; HUMAN PAPILLOMAVIRUS 18; INJECTIONS, INTRAMUSCULAR; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINES, DNA;

EID: 85020219718     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.05.081     Document Type: Article

References (37)

1. Wakeham, K., Kavanagh, K., The burden of HPV-associated anogenital cancers. Curr Oncol Rep, 16, 2014, 402.
2. Forman, D., de Martel, C., Lacey, C.J., Soerjomataram, I., Lortet-Tieulent, J., Bruni, L., et al. Global burden of human papillomavirus and related diseases. Vaccine 30:Suppl 5 (2012), F12–F23.
3. Maxwell, J.H., Grandis, J.R., Ferris, R.L., HPV-associated head and neck cancer: unique features of epidemiology and clinical management. Annu Rev Med, 2015.
4. Mehanna, H., Beech, T., Nicholson, T., El-Hariry, I., McConkey, C., Paleri, V., et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer–systematic review and meta-analysis of trends by time and region. Head Neck 35 (2013), 747–755.
5. Munoz, N., Bosch, F.X., de Sanjose, S., Herrero, R., Castellsague, X., Shah, K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003), 518–527.
6. Egawa, N., Egawa, K., Griffin, H., Doorbar, J., Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses 7 (2015), 3863–3890.
7. Walboomers, J.M., Jacobs, M.V., Manos, M.M., Bosch, F.X., Kummer, J.A., Shah, K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999), 12–19.
8. Dahlstrom, L.A., Ylitalo, N., Sundstrom, K., Palmgren, J., Ploner, A., Eloranta, S., et al. Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer 127 (2010), 1923–1930.
9. Chen, A.A., Gheit, T., Franceschi, S., Tommasino, M., Clifford Group IHVS, G.M., Human Papillomavirus 18 genetic variation and Cervical Cancer Risk Worldwide. J Virol 89 (2015), 10680–10687.
10. Schiller, J.T., Castellsague, X., Villa, L.L., Hildesheim, A., An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26:Suppl 10 (2008), K53–K61.
11. Yang, A., Farmer, E., Wu, T.C., Hung, C.F., Perspectives for therapeutic HPV vaccine development. J Biomed Sci, 23, 2016, 75.
12. Yang, A., Farmer, E., Lin, J., Wu, T.C., Hung, C.F., The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res 231 (2017), 148–165.
13. Lin, K.Y., Guarnieri, F.G., Staveley-O'Carroll, K.F., Levitsky, H.I., August, J.T., Pardoll, D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56 (1996), 21–26.
14. Wang, J.W., Jiang, R., Peng, S., Chang, Y.N., Hung, C.F., Roden, R.B., Immunologic control of Mus musculus papillomavirus Type 1. PLoS Pathog, 11, 2015, e1005243.
15. Zemmour, J., Little, A.M., Schendel, D.J., Parham, P., The HLA-A, B “negative” mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J Immunol 148 (1992), 1941–1948.
16. Zhao, L., Ren, J., Feng, J., Pang, Z., Zhang, Z.X., Tan, W.J., et al. (Trans.) Identification specific T lymphocyte epitopes on E6 protein of human papillomavirus type 18 in mice Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 24 (2010), 406–408.
17. McCarthy, C., Youde, S.J., Man, S., Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice. Int J Cancer 118 (2006), 2514–2521.
18. de Sanjose, S., Quint, W.G., Alemany, L., Geraets, D.T., Klaustermeier, J.E., Lloveras, B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11 (2010), 1048–1056.
19. Yang, A., Jeang, J., Cheng, K., Cheng, T., Yang, B., Wu, T.C., et al. Current state in the development of candidate therapeutic HPV vaccines. Exp Rev Vacc 15 (2016), 989–1007.
20. Oliveira, M.C., Soares, R.C., Pinto, L.P., Souza, L.B., Medeiros, S.R., Costa, Ade L., High-risk human papillomavirus (HPV) is not associated with p53 and bcl-2 expression in oral squamous cell carcinomas. Auris Nasus Larynx 36 (2009), 450–456.
21. Mathew, A., Mody, R.N., Patait, M.R., Razooki, A.A., Varghese, N.T., Saraf, K., Prevalence and relationship of human papilloma virus type 16 and type 18 with oral squamous cell carcinoma and oral leukoplakia in fresh scrappings: a PCR study. Indian J Med Sci. 65 (2011), 212–221.
22. Seraj, J.M., Yazdani, N., Ashtiani, Z.O., Seraj, S.M., Hasheminasab, S.M., Memar, B., et al. TP53 gene expression in HPV-positive oral tongue SCC and its correlation with nodal metastasis. Pathol Res Pract 207 (2011), 758–761.
23. Lee, L.A., Huang, C.G., Liao, C.T., Lee, L.Y., Hsueh, C., Chen, T.C., et al. Human papillomavirus-16 infection in advanced oral cavity cancer patients is related to an increased risk of distant metastases and poor survival. PLoS One, 7, 2012, e40767.
24. Peng, S., Ji, H., Trimble, C., He, L., Tsai, Y.C., Yeatermeyer, J., et al. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol 78 (2004), 8468–8476.
25. Chen, H.W., Leng, C.H., Liu, H.Y., Cheng, W.F., Chang, Y.W., Wu, P.Y., et al. Identification of HLA-A11-restricted CTL epitopes derived from HPV type 18 using DNA immunization. Cancer Biol Ther 8 (2009), 2025–2032.
26. Nimako, M., Fiander, A.N., Wilkinson, G.W., Borysiewicz, L.K., Man, S., Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer research. 57 (1997), 4855–4861.
27. Smith, K.L., Tristram, A., Gallagher, K.M., Fiander, A.N., Man, S., Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. Int Immunol 17 (2005), 167–176.
28. Gallagher, K.M., Man, S., Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women. J Gen Virol 88 (2007), 1470–1478.
29. Ribas, A., Butterfield, L.H., Amarnani, S.N., Dissette, V.B., Kim, D., Meng, W.S., et al. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells. Cancer Res 61 (2001), 8787–8793.
30. Brown, J.L., Barsoum, J., Qin, X.Q., CD4+ T helper cell-independent antitumor response mediated by murine IFN-beta gene delivery in immunocompetent mice. J Interferon Cytokine Res. 22 (2002), 719–728.
31. Lee, J.M., Merritt, R.E., Mahtabifard, A., Yamada, R., Kikuchi, T., Crystal, R.G., et al. Intratumoral expression of macrophage-derived chemokine induces CD4+ T cell-independent antitumor immunity in mice. J Immunother 26 (2003), 117–129.
32. Liu, D.W., Tsao, Y.P., Kung, J.T., Ding, Y.A., Sytwu, H.K., Xiao, X., et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 74 (2000), 2888–2894.
33. Marzo, A.L., Kinnear, B.F., Lake, R.A., Frelinger, J.J., Collins, E.J., Robinson, B.W., et al. Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol 165 (2000), 6047–6055.
34. Schietinger, A., Philip, M., Liu, R.B., Schreiber, K., Schreiber, H., Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med 207 (2010), 2469–2477.
35. Bos, R., Sherman, L.A., CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 70 (2010), 8368–8377.
36. Zhu, Z., Cuss, S.M., Singh, V., Gurusamy, D., Shoe, J.L., Leighty, R., et al. CD4+ T Cell Help Selectively Enhances High-Avidity Tumor Antigen-Specific CD8+ T Cells. J Immunol 195 (2015), 3482–3489.
37. Peng, S., Song, L., Knoff, J., Wang, J.W., Chang, Y.N., Hannaman, D., et al. Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells. Cell Biosci, 4, 2014, 11.